Delving into the Latest Updates on GD-N1702 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GD N1702, GD-N1702, GDN1702

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Chronic heart failure

Originator Organization

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

Active Organization-

Inactive Organization

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of GD-N1702 capsules after single and multiple oral administration in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of GD-N1702 capsules after single and multiple oral administration.

Start Date17 Oct 2022

Sponsor / Collaborator

Sichuan Gooddoctor Pharmaceutical Group Co. Ltd.

[+1]

ChiCTR2200064206

/ Not yet recruitingPhase 1IIT

A randomized, double-blind, placebo-controlled phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetics of GD-N1702 capsules administered in single and multiple doses in healthy subjects

Start Date09 Sep 2022

Sponsor / Collaborator-

100 Clinical Results associated with GD-N1702

Login to view more data

100 Translational Medicine associated with GD-N1702

Login to view more data

100 Patents (Medical) associated with GD-N1702

Login to view more data

100 Deals associated with GD-N1702

Login to view more data